Absci Corporation (ABSI)
| Market Cap | 390.34M |
| Revenue (ttm) | 6.94M |
| Net Income (ttm) | -106.49M |
| Shares Out | 92.94M |
| EPS (ttm) | -1.16 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 1,883,463 |
| Open | 4.78 |
| Previous Close | 4.60 |
| Day's Range | 4.13 - 4.86 |
| 52-Week Range | 1.11 - 5.47 |
| Beta | 1.54 |
| Analysts | Strong Buy |
| Price Target | 7.75 (+84.52%) |
| Earnings Date | Nov 14, 2023 |
About ABSI
Absci Corporation operates as a generative AI drug creation company in the United States. Its integrated drug creation platform identifies novel drug targets and creates biotherapeutic candidates. The company was founded in 2011 and is headquartered in Vancouver, Washington. [Read more]
Financial Performance
In 2022, Absci's revenue was $5.75 million, an increase of 20.18% compared to the previous year's $4.78 million. Losses were -$104.90 million, 1.61% more than in 2021.
Financial StatementsAnalyst Forecast
According to 4 analysts, the average rating for ABSI stock is "Strong Buy." The 12-month stock price forecast is $7.75, which is an increase of 84.52% from the latest price.
News
Absci to Participate in the 42nd Annual J.P. Morgan Healthcare Conference
VANCOUVER, Wash. and NEW YORK, Dec. 28, 2023 (GLOBE NEWSWIRE) -- Absci Corporation (Nasdaq: ABSI), a generative AI drug creation company, today announced the company will be participating in the upcom...
Absci and PrecisionLife Announce Strategic R&D Partnership to Jointly Develop AI-Enabled Drug Pipeline
Leading AI biologics and precision medicine innovators will harness technologies to build a diverse portfolio of novel drug treatments With this partnership, Absci achieves 2023 outlook of ten new Act...
Absci Announces Collaboration with AstraZeneca to Advance AI-Driven Oncology Candidate
Collaboration Combines Absci's AI Antibody Drug Creation Platform with AstraZeneca's Expertise in Oncology Research and Development Collaboration Combines Absci's AI Antibody Drug Creation Platform wi...
AstraZeneca, AI biologics firm Absci tie up on cancer drug - FT
Anglo-Swedish drugmaker AstraZeneca has signed a deal worth up to $247 million with U.S. artificial intelligence (AI) biologics firm Absci to design an antibody to fight cancer, the Financial Times re...
Absci to Participate in the Piper Sandler 35th Annual Healthcare Conference
VANCOUVER, Wash. and NEW YORK, Nov. 15, 2023 (GLOBE NEWSWIRE) -- Absci Corporation (Nasdaq: ABSI), a generative AI drug creation company, today announced the company will be participating in the upcom...
Absci Reports Business Updates and Third Quarter 2023 Financial and Operating Results
Entered into partnership with Almirall to rapidly develop novel treatments for dermatological diseases, for up to $664M in deal value, plus royalties
Almirall and Absci announce AI drug discovery partnership to rapidly develop novel treatments for dermatological diseases
BARCELONA, Spain & VANCOUVER, Wash.--(BUSINESS WIRE)--Almirall S.A. (BME: ALM), a global biopharmaceutical company focused on medical dermatology, and Absci Corporation (Nasdaq: ABSI), a generative AI...
Absci to Participate in Upcoming Investor Conferences
VANCOUVER, Wash. and NEW YORK, Oct. 26, 2023 (GLOBE NEWSWIRE) -- Absci Corporation (Nasdaq: ABSI), a generative AI drug creation company, today announced the company will be participating in the follo...
Absci Announces Speaker Lineup for Inaugural R&D Day, Including Renowned Global Business Leader Sandi Peterson and VP of Applied Research at NVIDIA Jonathan Cohen
VANCOUVER, Wash. and NEW YORK, Sept. 21, 2023 (GLOBE NEWSWIRE) -- Absci Corporation (Nasdaq: ABSI), a generative AI drug creation company, today announced the speaker lineup for its inaugural R&D Day ...
Absci to Host R&D Day on October 4, 2023
VANCOUVER, Wash. and NEW YORK, Sept. 06, 2023 (GLOBE NEWSWIRE) -- Absci Corporation (Nasdaq: ABSI), a generative AI drug creation company, today announced the company will host its first R&D Day on We...
Biotech company Absci lays off 30 employees, about 15% of staff
Publicly traded biotech company Absci is laying off 30 employees, or approximately 15% of its workforce.
Absci Reports Business Updates and Second Quarter 2023 Financial and Operating Results
Entered into partnership with Google Ventures-backed biotech company to discover innovative new medicines Entered into collaboration with Caltech, supported by the Gates Foundation, to discover afford...
Absci Appoints Zach Jonasson, Ph.D., as Chief Financial Officer and Chief Business Officer
Addition of veteran biotech leader to further support Absci's next stage of growth Addition of veteran biotech leader to further support Absci's next stage of growth
Absci and Caltech Join Forces, Bolstered by Major Grant, to Accelerate Affordable HIV Therapeutic Vaccine Development
VANCOUVER, Wash., Aug. 10, 2023 (GLOBE NEWSWIRE) -- Absci Corporation (Nasdaq: ABSI), a generative AI drug creation company, today announced that leading researchers at the California Institute of Te...
Absci to Participate in the UBS MedTech, Tools and Genomics Summit 2023
VANCOUVER, Wash. and NEW YORK, Aug. 01, 2023 (GLOBE NEWSWIRE) -- Absci Corporation (Nasdaq: ABSI), a generative AI drug creation company, today announced the company will be participating in the upcom...
Absci to Participate in the Morgan Stanley 2nd Annual Biotechnology AI Summit
VANCOUVER, Wash. and NEW YORK, June 15, 2023 (GLOBE NEWSWIRE) -- Absci Corporation (Nasdaq: ABSI), a generative AI drug creation company, today announced the company will be participating in the upcom...
Absci Evolves its Board of Directors with HealthTech Luminary Frans van Houten, Former CEO of Philips
VANCOUVER, Wash., June 06, 2023 (GLOBE NEWSWIRE) -- Absci (Nasdaq: ABSI), a generative AI drug creation company, today announced the appointment of Frans van Houten to its Board of Directors. With his...
Absci Reports Business Updates and First Quarter 2023 Financial and Operating Results
Commenced work plan preparations and expect to initiate program work during second quarter leveraging Absci's generative AI drug creation platform for Phase II candidate
University of Oxford's Kennedy Institute of Rheumatology Partners with Absci to Accelerate AI-Driven Immunotherapies
Absci will apply its generative AI platform to The Kennedy Institute's immunology biorepository to speed the discovery and development of multiple therapies Absci will apply its generative AI platform...
Absci to Participate in the 22nd Annual Needham Virtual Healthcare Conference
VANCOUVER, Wash. and NEW YORK, April 06, 2023 (GLOBE NEWSWIRE) -- Absci Corporation (Nasdaq: ABSI), a generative AI drug creation company, today announced the company will be participating in the upco...
Absci Reports Fourth Quarter and Full Year 2022 Financial and Operating Results
Advanced platform achieving multiple industry breakthroughs including creation and validation of de novo antibodies using zero-shot generative AI
Absci to Participate in the B. Riley Securities' Life Sciences Tools Conference - Proteomics Setting the Blueprint for Innovative Drug Creation
VANCOUVER, Wash. and NEW YORK, March 23, 2023 (GLOBE NEWSWIRE) -- Absci Corporation (Nasdaq: ABSI), a generative AI drug creation company, today announced the company will be participating virtually i...
Absci to Participate in the KeyBanc Capital Markets Life Sciences & MedTech Investor Forum
VANCOUVER, Wash. and NEW YORK, March 07, 2023 (GLOBE NEWSWIRE) -- Absci Corporation (Nasdaq: ABSI), a generative AI drug creation company, today announced the company will be participating virtually i...
Absci Takes Its Generative AI Antibody Design Platform To Europe
Generative AI technology, like ChatGPT, is disrupting many industries including biopharma. For example, Absci is using AI to design & validate de novo antibodies.
Absci to Participate in the 43rd Annual Cowen Health Care Conference
VANCOUVER, Wash. and NEW YORK, Feb. 21, 2023 (GLOBE NEWSWIRE) -- Absci Corporation (Nasdaq: ABSI), a generative AI drug creation company, today announced the company will be participating in the upcom...